Proton Bio
Empowering breakthroughs in Cell and Gene Therapy with comprehensive development and manufacturing solutions.
Empowering breakthroughs in Cell and Gene Therapy with comprehensive development and manufacturing solutions.
Proton Bio, a leader in Cell and Gene Therapy (CGT) solutions, is revolutionizing the biopharma and biotechnology industries with its comprehensive development and manufacturing services. Since its establishment in 2018, the company has been empowering breakthroughs in CGT, offering a range of services including process development, analytical development, GMP manufacturing, and testing at every stage from pre-clinical to commercialization. The recent CNY520.00M Series B investment on 19 August 2022 from an impressive lineup of investors including Hillhouse Investment, Huatai Health Fund, Huimei Capital, Advanced Manufacturing Industry Investment Fund, China Merchants Venture Capital, China Merchants Securities, Fosun Pharma, Huatai Zijin Investment further underscores Proton Bio's potential for growth and impact in the industry. With its mission to meet the evolving demands of the CGT sector, Proton Bio is poised for significant advancements and market influence.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | CNY520.00M | 8 |
|
19 Aug 2022 |
No recent news or press coverage available for Proton Bio.
We care about your data, and we'd love to use cookies make your experience better.